Clinical Trials & Research

Reviewed by Emily Henderson, B.Sc.Nov 10 2020 Northern Arizona University researcher Jeff Foster is leading an international effort to study and track the spread of one of the most important infectious diseases in humans and livestock worldwide. Brucellosis infects an estimated 500,000 people and millions of animals each year – cattle, pigs, sheep, goats –
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) November 3, 2020 — Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-1 evaluated 6 mg of deucravacitinib once
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 6 2020 New research shows that children with Kawasaki Disease remain at an increased risk for cardiovascular events more than 10 years after hospitalization for their condition, highlighting the need for long-term heart disease surveillance and risk reduction strategies for these young patients. Details of the study was presented at
0 Comments
OSLO, Norway and CHENGDU, China. 03 November,2020— CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based  S-Trimer COVID-19 vaccine candidate by Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover”) through a global pivotal Phase 2/3 efficacy clinical trial and to licensure in China and globally, if the vaccine is
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 6 2020 A new study led by Maria Manuel Mota, group leader at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal), now shows that malaria parasites secrete the protein EXP2 that is required for their entry into hepatocytes. These findings, published today in the scientific journal Nature Communications, open
0 Comments
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community. “This arrangement with the
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 3 2020 Researchers at the University of Bern led an international team that has identified a novel vulnerability in advanced prostate cancer that is no longer responding to hormonal therapy. These findings could lead to the development of new treatment approaches for men suffering from the most aggressive form of
0 Comments
NEW YORK–(BUSINESS WIRE) October 27, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 30 2020 The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their
0 Comments
INDIANAPOLIS, Oct. 28, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food
0 Comments
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Preliminary results from the first five patients treated
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 28 2020 The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, deputy director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the University
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 26, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early
0 Comments
Oct 26 2020 Huron Digital Pathology announced today that the Joint Pathology Center (JPC), the premier pathology reference center for the United States federal government and part of the US Defense Health Agency, has selected Huron’s artificial intelligence-enabled LagottoTM image search engine to index and search JPC’s growing digital image archive, as part of JPC’s
0 Comments
21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. In the midst of the global pandemic, the analysis found
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 23 2020 The results of a new clinical trial, published today in the New England Journal of Medicine, show that dexamethasone- a glucocorticoid used to treat many conditions, including rheumatic problems and severe COVID-19- can boost survival of premature babies when given to pregnant women at risk of preterm birth
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 22 2020 Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) October 16, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating Keytruda, Merck’s anti-PD-1 therapy: Keytruda in combination with chemotherapy (KEYNOTE-021 [Cohort G]) and Keytruda in combination with quavonlimab (MK-1308),
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 Patients with thyroid dysfunction are routinely treated with drugs to regulate the hormone imbalance. The effect of these drugs is clinically evaluated by means of blood tests. A team led by Michael Krebs from MedUni Vienna’s Division of Endocrinology and Metabolism has now conducted a study to test
0 Comments
October 16, 2020 — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 18 2020 Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 13, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows positive results from a preclinical viral challenge study of
0 Comments
Oct 16 2020 More than 50 anesthetists across Australia have participated in a new video campaign that highlights how they are ‘always ready’ on the medical frontline. To mark National Anesthesia Day, they produced 90-second videos explaining why they are always ready. The slogan referred to the challenging months that many of them have experienced
0 Comments
October 13, 2020 — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which
0 Comments
Oct 14 2020 Irvine, CA (10/09/2020) – Advantech announced today that MIC-730AI, Edge AI Inference System based on NVIDIA Jetson® Xavier has received a 2020 IoT Edge Computing Excellence Award from IoT Evolution World, the leading web site covering the Internet of Things (IoT) marketplace. This award recognizes the companies emerging as leaders in the
0 Comments